IBDEI2GA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41560,1,4,0)
 ;;=4^A60.04
 ;;^UTILITY(U,$J,358.3,41560,2)
 ;;=^5000356
 ;;^UTILITY(U,$J,358.3,41561,0)
 ;;=A60.01^^159^2006^32
 ;;^UTILITY(U,$J,358.3,41561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41561,1,3,0)
 ;;=3^Herpesviral Infection of Penis
 ;;^UTILITY(U,$J,358.3,41561,1,4,0)
 ;;=4^A60.01
 ;;^UTILITY(U,$J,358.3,41561,2)
 ;;=^5000353
 ;;^UTILITY(U,$J,358.3,41562,0)
 ;;=B00.1^^159^2006^33
 ;;^UTILITY(U,$J,358.3,41562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41562,1,3,0)
 ;;=3^Herpesviral Vesicular Dermatitis
 ;;^UTILITY(U,$J,358.3,41562,1,4,0)
 ;;=4^B00.1
 ;;^UTILITY(U,$J,358.3,41562,2)
 ;;=^5000468
 ;;^UTILITY(U,$J,358.3,41563,0)
 ;;=B97.89^^159^2006^89
 ;;^UTILITY(U,$J,358.3,41563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41563,1,3,0)
 ;;=3^Viral Agent Cause of Disease
 ;;^UTILITY(U,$J,358.3,41563,1,4,0)
 ;;=4^B97.89
 ;;^UTILITY(U,$J,358.3,41563,2)
 ;;=^5000879
 ;;^UTILITY(U,$J,358.3,41564,0)
 ;;=B97.10^^159^2006^21
 ;;^UTILITY(U,$J,358.3,41564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41564,1,3,0)
 ;;=3^Enterovirus Cause of Disease
 ;;^UTILITY(U,$J,358.3,41564,1,4,0)
 ;;=4^B97.10
 ;;^UTILITY(U,$J,358.3,41564,2)
 ;;=^5000861
 ;;^UTILITY(U,$J,358.3,41565,0)
 ;;=B34.9^^159^2006^90
 ;;^UTILITY(U,$J,358.3,41565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41565,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,41565,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,41565,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,41566,0)
 ;;=A69.20^^159^2006^50
 ;;^UTILITY(U,$J,358.3,41566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41566,1,3,0)
 ;;=3^Lyme Disease,Unspec
 ;;^UTILITY(U,$J,358.3,41566,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,41566,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,41567,0)
 ;;=A69.22^^159^2006^52
 ;;^UTILITY(U,$J,358.3,41567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41567,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,41567,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,41567,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,41568,0)
 ;;=A69.21^^159^2006^51
 ;;^UTILITY(U,$J,358.3,41568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41568,1,3,0)
 ;;=3^Meningitis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,41568,1,4,0)
 ;;=4^A69.21
 ;;^UTILITY(U,$J,358.3,41568,2)
 ;;=^5000376
 ;;^UTILITY(U,$J,358.3,41569,0)
 ;;=A69.29^^159^2006^18
 ;;^UTILITY(U,$J,358.3,41569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41569,1,3,0)
 ;;=3^Conditions d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,41569,1,4,0)
 ;;=4^A69.29
 ;;^UTILITY(U,$J,358.3,41569,2)
 ;;=^5000379
 ;;^UTILITY(U,$J,358.3,41570,0)
 ;;=A69.23^^159^2006^5
 ;;^UTILITY(U,$J,358.3,41570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41570,1,3,0)
 ;;=3^Arthritis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,41570,1,4,0)
 ;;=4^A69.23
 ;;^UTILITY(U,$J,358.3,41570,2)
 ;;=^5000378
 ;;^UTILITY(U,$J,358.3,41571,0)
 ;;=A51.0^^159^2006^29
 ;;^UTILITY(U,$J,358.3,41571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41571,1,3,0)
 ;;=3^Genital Syphilis,Primary
 ;;^UTILITY(U,$J,358.3,41571,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,41571,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,41572,0)
 ;;=A52.3^^159^2006^54
 ;;^UTILITY(U,$J,358.3,41572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41572,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,41572,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,41572,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,41573,0)
 ;;=A52.10^^159^2006^53
 ;;^UTILITY(U,$J,358.3,41573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41573,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,41573,1,4,0)
 ;;=4^A52.10
